2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Thoracic
1
Conditions
Urinary Bladder Neoplasms
2
Hormone Refractory Prostate Cancer
1
Interventions
Docetaxel
409
pembrolizumab
332
Prednisone
290
enzalutamide
285
Gemcitabine
274
Radiotherapy
270
Magnetic Resonance Spectroscopy
269
Nivolumab
253
Abiraterone Acetate
218
Cisplatin
212
Leuprolide
195
Radiosurgery
192
Sunitinib
188
Carboplatin
161
Androgen Antagonists
156
bicalutamide
152
Specimen Handling
149
Goserelin
149
Ipilimumab
131
Paclitaxel
126
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
122
apalutamide
118
Cyclophosphamide
117
Bevacizumab
116
Sorafenib
114
Everolimus
111
abiraterone
108
cabozantinib
105
atezolizumab
105
Biopsy
101
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Mycobacterium w vaccine
×
Genitourinary
×
Clear all
NCT00694915
2021-08-17
STCC
Cadila Pharnmaceuticals
Phase 2
Completed
122 enrolled
NCT00694798
2012-05-03
STCC
Cadila Pharnmaceuticals
Phase 1
Completed
22 enrolled
NCT00525408
2012-03-12
HRPC
Cadila Pharnmaceuticals
Phase 2
Terminated
134 enrolled